The Non-HIV Anti-Infective Therapeutics Special Emphasis Panel [IDM (10)] reviews Small Business Innovation Research [SBIR] and Small Business Technology Transfer Research [STTR] grant applications that focus on the development of therapeutic agents to combat bacterial, viral, fungal, parasitic, prion infections and disease vectors.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
- Development and/or testing of novel anti-infective agents or therapeutic process to fight infective agents using culture systems or animal models.
- Development of traps, biocides or pesticides active against infectious disease vectors.
- Development of processes to optimize industrial production of non-HIV anti-infective agents.
Overlaps with Closely Related Study Sections
There are shared interests with Small Business: Non-HIV Infectious Agent Detection/Diagnostics, Food Safety, Sterilization/Disinfection and Bioremediation Special Emphasis Panel (IDM (12)) in the advancement of anti-infective approaches. Grant applications addressing the development of agents or methods to detect or combat biofilms in vivo and on medical devices may be reviewed in IDM (12). Applications that seek to develop antibiotic agents that include effectiveness in the context of biofilms may be reviewed in IDM (10).
There are shared interests with Small Business: Biological Chemistry, Biophysics, and Assay Development (IMST (10)) in the advancement of anti-infective approaches. Applications addressing the development of reagents and reporters of bioassays may be reviewed in IMST (10) if the focus is on the chemistry. If the focus of such applications is on the microbiology, they may be reviewed in IDM (10).
There are shared interests with Small Business: Computational, Modeling, and Biodata Management (IMST (14)) in the advancement of anti-infective approaches. Grant applications that address computational modeling, image processing and systems biology approaches for antimicrobial drug development may be reviewed in IMST (14) if the focus is on the development of the technology. If the focus of such applications is on the utilization of the technology for drug development, they may be reviewed in IDM (10).
There are shared interests with Small Business: Drug Discovery and Development (BCMB (10)) in the advancement of anti-infective approaches. Grant applications that address development of synthetic small molecules and natural products, or address large-scale synthesis for the manufacture of antimicrobial drugs, or seek to advance computational approaches to the discovery of antimicrobial agents, or advance assay development and screening techniques to support antimicrobial development may be reviewed in BCMB (10). Applications that screen small molecule libraries for anti-infective activity may be reviewed in IDM (10).
There are shared interests with Small Business: Innovative Immunology Research (IMM (10)) in the advancement of anti-infective approaches. Grant applications that advance the development of immunologic therapies, or an agent used against diseases of immunologic origin or that focus on basic or applied immunology may be reviewed in IMM (10). Applications that focus on therapeutics where immunological components are not the major component may be reviewed in IDM (10).